Sympathetic nervous activation in obesity and the metabolic syndrome-Causes, consequences and therapeutic implications

被引:245
|
作者
Lambert, Gavin W. [1 ]
Straznicky, Nora E. [1 ,2 ,3 ]
Lambert, Elisabeth A. [1 ,2 ,3 ]
Dixon, John B. [1 ,4 ]
Schlaich, Markus P. [1 ,2 ,3 ]
机构
[1] Baker IDI Heart & Diabet Inst, Human Neurotransmitters Lab, Melbourne, Vic 8008, Australia
[2] Baker IDI Heart & Diabet Inst, Neurovasc Hypertens Lab, Melbourne, Vic 8008, Australia
[3] Baker IDI Heart & Diabet Inst, Kidney Dis Lab, Melbourne, Vic 8008, Australia
[4] Monash Univ, Obes Res Ctr, Dept Gen Practice, Clayton, Vic 3800, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
Overweight; Metabolic syndrome; Sympathetic nervous system; Microneurography; Target organ damage; BODY-MASS-INDEX; CONVERTING ENZYME-INHIBITION; POSITIVE AIRWAY PRESSURE; LEFT-VENTRICULAR MASS; CARDIOVASCULAR RISK-FACTORS; PREDICT INSULIN-RESISTANCE; MAJOR DEPRESSIVE DISORDER; SLEEP-APNEA SYNDROME; 3RD NATIONAL-HEALTH; END-POINT REDUCTION;
D O I
10.1016/j.pharmthera.2010.02.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The world wide prevalence of obesity and the metabolic syndrome is escalating. Contrary to earlier experimental evidence, human obesity is characterised by sympathetic nervous activation, with the outflows to both the kidney and skeletal muscle being activated. While the mechanisms responsible for initiating the sympathetic activation remain to be unequivocally elucidated, hyperinsulinemia, obstructive sleep apnoea, increased circulating adipokines, stress and p adrenergic receptor polymorphisms are implicated. The pattern of sympathetic activation may be the pathophysiological mechanism underpinning much obesity-related illnesses with the consequences including, amongst others, the development of hypertension, insulin resistance, diastolic dysfunction and renal impairment. While diet and exercise are the first line therapy for the treatment of obesity and the metabolic syndrome, pharmacological interventions targeting the sympathetic nervous system, either directly or indirectly are also likely to be of benefit. Importantly, the benefit may not necessarily be weight related but may be associated with a reduction in end organ damage. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:159 / 172
页数:14
相关论文
共 50 条
  • [41] The metabolic syndrome in hypertension: Diagnostic and therapeutic implications
    Josep Redon
    Renata Cífková
    Current Hypertension Reports, 2007, 9
  • [42] Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications
    Kalil, Graziela Z.
    Haynes, William G.
    HYPERTENSION RESEARCH, 2012, 35 (01) : 4 - 16
  • [43] Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications
    Graziela Z Kalil
    William G Haynes
    Hypertension Research, 2012, 35 : 4 - 16
  • [44] Obesity and Metabolic Syndrome (MS) in Adolescence - Therapeutic Options
    Wabitsch, M.
    PROCEEDINGS OF THE 13TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY, 2008, : 165 - 173
  • [45] Therapeutic approaches to obesity and metabolic syndrome in children and adolescents
    Chung, Sochung
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2018, 61 (10): : 599 - 606
  • [46] Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations
    Nikoletta Mili
    Stavroula A. Paschou
    Dimitrios G. Goulis
    Meletios-Athanasios Dimopoulos
    Irene Lambrinoudaki
    Theodora Psaltopoulou
    Endocrine, 2021, 74 : 478 - 497
  • [47] Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations
    Mili, Nikoletta
    Paschou, Stavroula A.
    Goulis, Dimitrios G.
    Dimopoulos, Meletios-Athanasios
    Lambrinoudaki, Irene
    Psaltopoulou, Theodora
    ENDOCRINE, 2021, 74 (03) : 478 - 497
  • [48] Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome
    Abu Saleh Md Moin
    Thozhukat Sathyapalan
    Ilhame Diboun
    Mohamed A. Elrayess
    Alexandra E. Butler
    Stephen L. Atkin
    Scientific Reports, 11
  • [49] Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome
    Moin, Abu Saleh Md
    Sathyapalan, Thozhukat
    Diboun, Ilhame
    Elrayess, Mohamed A.
    Butler, Alexandra E.
    Atkin, Stephen L.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [50] GNB3 overexpression causes obesity and metabolic syndrome
    Ozdemir, Alev Cagla
    Wynn, Grace M.
    Vester, Aimee
    Weitzmann, M. Neale
    Neigh, Gretchen N.
    Srinivasan, Shanthi
    Rudd, M. Katharine
    PLOS ONE, 2017, 12 (12):